S
ince the introduction of the first commercial ultrasound (US) contrast agents in the 1990s, substantial improvement has been accomplished. 1 Indeed, first-generation US contrast agents, made of stabilized encapsulated gaseous microbubbles, showed relatively low persistence, resulting in a limited circulation time, mostly due to the type of the stabilizing structure, the relative high solubility of the gas core (eg, air), or both. Nowadays, all marketed US contrast agents comprise microbubbles with a stabilizing shell made of, eg, lipids or proteins and fluorinated gases with a high molecular weight and very low solubility in water; as a result, the microbubbles dissolve more slowly in the blood, providing longer persistence. After a relatively long period of acceptance, contrast-enhanced US has now reached the stage of maturity and has shown a continuous increase in market share over the years, primarily due to its sensitive, safe, inexpensive, and portable nature. Moreover, contrast-enhanced US is a modality considered equivalent or superior to existing modalities such as computed tomography, magnetic resonance imaging, and nuclear medicine. 2 Contrast-enhanced US permits real-time visualization of contrast enhancement patterns in various organs. In that respect, it is most often used for liver imaging, particularly for the characterization of focal liver lesions, 3 but has also shown its usefulness in several other clinical applications. In echocardiography, left ventricle (LV) opacification and endocardial border delineation facilitate wall motion abnormality assessment, 4 whereas in radiology, indications include gastrointestinal as well as nongastrointestinal organs such as the spleen, 5 kidneys, 6 and breast. 7 Moreover, thanks to the capacity to image both macrovasculature and microvasculature, contrastenhanced US has also expanded to new applications, in which a perfusion abnormality can be an indicator of a defined pathologic condition. For example, contrastenhanced US imaging has also emerged as a novel diagnostic tool, eg, to measure intraplaque neovascularization, 8 to detect endoleaks after endovascular treatment of abdominal aortic aneurysms, 9 or to detect potential perfusion deficits in transplanted kidneys. 10 Similarly, contrast-enhanced US combined with standardized protocols and quantification software has emerged as a potential tool for monitoring functional changes in response to antitumoral therapy. In this respect, contrast-enhanced US has been shown to predict gastrointestinal stromal tumor responses to antiangiogenic therapy, 11 metastatic renal cell carcinoma responses to sunitinib, 12, 13 and hepatocellular carcinoma responses to sorafenib.
14 No doubt that more clinical applications requiring assessment of tissue perfusion in real time will emerge in the near future, along with improvements in US scanners and imaging methods.
Today, 4 US contrast agents are commercially available: namely, Definity (perflutren lipid microspheres; Lantheus Medical Imaging, North Billerica, MA), Sonazoid (perflubutane microbubbles; GE Healthcare; Little Chalfont, England), SonoVue (sulfur hexafluoride microbubbles; Bracco Imaging SpA, Colleretto Giacosa, Italy; also marketed as Lumason in the United States; sulfur hexafluoride lipid type A microspheres; Bracco Diagnostics Inc, Monroe Township, NJ), and Optison (perflutren protein type A microspheres, GE Healthcare AS, Oslo, Norway). The first 3 agents are composed of microbubbles stabilized with a phospholipid envelope, whereas the latter is the only US contrast agent comprising an envelope of a protein nature (denatured albumin). These microbubbles have a diameter of less than 8 lm and are formulated with fluorinated gases. Although some of these agents have been marketed for more than 15 years, very few studies have compared their imaging performance in terms of enhancement and persistence, which might be the result of a favorable competitive environment. Indeed, today Sonazoid is the only US contrast agent commercialized in Japan, whereas SonoVue is available in China and Europe. For the United States, the market is dominated by Definity, followed by Optison (only approved for LV opacification) and Lumason; the latter, being available only since the end of 2014, is approved for LV opacification and recently also for focal liver lesion characterization in adult and pediatric patients. With this in mind, it was decided to compare in vitro and in vivo imaging performances in a preclinical evaluation of 3 of these agents: SonoVue, Definity and Optison. In addition, physicochemical characteristics of the agents are also reported.
Materials and Methods

Contrast Agents
SonoVue or Lumason is supplied as a kit containing a single-use vial of phospholipid lyophilized powder and sulfur hexafluoride head space, a prefilled syringe with 5 mL of a sodium chloride 0.9% injection (diluent), and a Mini-Spike transfer system.
The Definity injectable suspension is supplied as a single-use 2-mL glass vial containing clear liquid; packages contain 4 or 16 single-use vials. Definity microbubbles were activated by shaking the vial for 45 seconds using the Vialmix (Lantheus Medical Imaging). The product was used 5 minutes after activation.
Optison is supplied as a single-use 3-mL glass vial containing clear liquid with a white layer on top; packages contain 5 single-use vials. For all agents, microbubbles were resuspended before use by gentle hand agitation of the vial.
Physicochemical Characterization
Size distributions and microbubble concentrations were measured with a Multisizer Coulter Counter (Beckman Coulter, Fullerton, CA) using an aperture tube with a diameter of 30 lm. The standard aperture range is 2% to 60% of the aperture diameter, which results in diameters measured between 0.6 and 18 lm. Parameters such as the mean microbubble diameter in number and median microbubble diameter in volume are derived from the measured size distributions and provided by the Coulter Counter software.
Ultrasound Systems
Two US systems with different transducers were used to measure contrast enhancement at frequencies that are typically used for different clinical indications, such as cardiac, abdominal, and small parts. An Aplio 500 system (Toshiba Medical Systems Corp, Tochigi-ken, Japan) was used with a 6C1 curvilinear transducer. A Logiq E9 system (GE Healthcare, Little Chalfont, England) was used with 9L linear, C1-6 curvilinear, and M5S phased array transducers. Systems, transducers, and mechanical indices (MIs) used are listed in Table 1 . Other settings, such as gain, dynamic range, time-gain compensation, focus, and depth were fixed for each system.
In Vitro Measurements
An in-house setup ( Figure 1A , top) was built and consisted of a beaker filled with 800 mL of saline (0.9% sodium chloride; B. Braun Medical, Sempach, Switzerland). The beaker was placed on a magnetic stirrer (Ikamag RCT; IKA-Labortechnik, Staufen, Germany) to homogenize the contrast agent suspensions. A 1-cm-thick acoustic absorber (Aptflex F28; Precision Acoustics, Dorchester, England) was placed at the bottom of the beaker to minimize acoustic reflections. An L-shaped tissue-mimicking phantom (ATS Laboratories, Inc, Bridgeport, CT) was placed in the beaker directly below the transducer. The phantom had a depth of 33 mm on one side and 90 mm on the other side, creating a cavity where contrast enhancement could be measured at different depths, in an upper region of interest (ROI) located directly below the phantom (about 4 cm deep from the transducer) and in a lower ROI located approximately 3 cm deeper: ie, about 7 cm deep from the transducer ( Figure 1A , bottom). Different agent concentrations were prepared by successively adding the agent in the beaker and are expressed in microliters of gas per milliliter.
Sequences of images of about 4 seconds were acquired at a 10-Hz frame rate. The image sequences were exported in the Digital Imaging and Communications in Medicine format and processed offline with VueBox quantification software (Bracco Suisse SA, Plan-les-Ouates, Switzerland). Data were linearized to establish direct proportionality between the local microbubble concentration and the echo signals. 15 Proportionality between microbubble scattering and agent concentration is a prerequisite for accurate quantification. The mean scattered echo power was then calculated in the two ROIs as a function of agent concentration at two depths. In this way, scattered echo signals from the microbubbles without attenuation can be assessed in the upper ROI, whereas scattered echo signals affected by attenuation, when the US beam traverses a volume with microbubbles, can be assessed at the same time in the lower ROI.
Animal Models and In Vivo Measurements
All experiments were performed under the authorization of the Direction G en erale de la Sant e (Geneva, Switzerland; GE/112/14, and GE/7/15). Farm pigs (n 5 5; mean weight, 29.6 6 0.8 kg) were premedicated with a mixture of azaperone at 4.5 mg/kg (Stresnol; Janssen, Bern, Switzerland) and midazolam at 0.3 mg/ kg (Dormicum; Roche, Basel, Switzerland). Anesthesia was induced by intravenous injection of thiopental at 20 mg/kg (Penthotal; Ospedalia AG, H€ unenberg, Switzerland) and further maintained by an infusion of a mixture thiopental (5-8 mg/h) plus fentanyl (0.5 lg/kg/h; Sandoz Pharmaceuticals AG, Rotkreuz, Switzerland). Animals were mechanically ventilated. The heart rate, body temperature, inspired fraction of oxygen, end-tidal fraction of carbon dioxide, and saturation of peripheral oxygen were monitored during the examination. All pigs received an intravenous injection of aspirin (10 mg/kg, AspegicInject; Sanofi, Vernier, Switzerland) 30 minutes The MI values were based on recommendations provided by the manufacturers. Figure 1 . In vitro comparison of US contrast agent (UCA) imaging performance. A, Experimental setup. B, and C, Scattered power as a function of agent concentration in the upper ROI (B) and in the lower ROI (C); both were obtained with the Logiq E9 US system using the 9L transducer. D, Normalized scattered power, based on the mean scattering for concentrations between 10 24 and 10 23 lL/mL, calculated in the upper ROI. E, Normalized performance index, which is based on an apparent scattering-to-attenuation ratio determined in the lower ROI at the concentration of 10 23 lL/mL. Data were normalized to those of SonoVue. Note: Optison data were not available for the GE Logiq E9 system with the M5S phased array transducer.
before injection of the contrast agent to prevent the activation of pulmonary intravascular macrophages. 16 Rabbits (n 5 3; weight, 3.3 6 0.5 kg) were anesthetized with isoflurane inhalation at 5% in oxygen (1 L/ min). Anesthesia was maintained with isoflurane at 1.5% to 2% in air (0.8 L/min). The heart rate, saturation of peripheral oxygen, and body temperature were monitored during the examination.
The contrast agents were reconstituted according to the manufacturer's instructions and were injected intravenously in the auricular vein, followed by a saline flush (0.9% sodium chloride). The agents were injected at full and half clinical doses: ie, 34 and 17 lL/kg (2.4 and 1.2 mL/bolus for a 70-kg person) for SonoVue, 17-20 3 and 1.5 lL/kg (0.2 and 0.1 mL/bolus for a 70-kg person) for Definity, [21] [22] [23] [24] and 15 and 7.5 lL/kg, (1 and 0.5 mL/bolus for a 70-kg person) for Optison. [25] [26] [27] [28] [29] Each injection was repeated twice in randomized order.
The US systems, transducers, and settings used are listed in Table 2 ; settings were defined according to the manufacturers' instructions. Image sequences of 1 minute were acquired immediately after injection. Then acquisition was stopped and restarted at 2, 3, 4, 5, and 10 minutes after injection for acquiring 10-second sequences; acquisition was interrupted to minimize possible bubble destruction between the acquisition periods. The image sequences were exported in the Digital Imaging and Communications in Medicine format, and contrast enhancement was analyzed with VueBox quantification software.
Results
Physicochemical Characterization
From native activated/reconstituted vials of US contrast agents, the microbubble concentration of Definity (120 3 10 8 microbubbles/mL) is approximately 25 times higher than that of SonoVue, and its mean microbubble diameter in number is smaller (diameters in number of 1.2 and 1.9 lm for Definity and SonoVue, respectively). For Optison, the microbubble concentration is approximately twice that of SonoVue, and its mean microbubble diameter is larger (diameters in number of 3.1 and 1.9 lm for Optison and SonoVue, respectively; Table 3 ). These physicochemical characteristics are in agreement with those provided by the manufacturers. The median diameter in volume is similar for all 3 agents (8.0 lm).
The fraction of microbubbles with diameters smaller than 10 lm is more than 99% for both SonoVue and Definity. The microbubble volume concentrations are 6.5, 44.0, and 35.2 lL of gas/mL for SonoVue, Definity, and Optison, respectively, and are in agreement with the specifications provided by the manufacturers (Table 3) . Despite these differences, it is also important to take into account the clinical dosage used for each agent. Table 4 summarizes the total amount of shell material, gas volume, and microbubbles injected at full and half clinical doses. These numbers are in the same range for SonoVue and Definity. Comparing SonoVue with Optison reveals no difference in terms of total gas volume and number of microbubbles injected, but the amount of shell material (expressed in micrograms per kilogram) is 50 times higher for Optison compared to SonoVue.
In Vitro Measurements
For all 3 agents, the scattering in the upper ROI ( Figure  1B) increases proportionally with the agent concentration, as expected and indicated by the dashed black line, which has a slope of 10 dB/decade. 30 This proportionality is shown for concentrations ranging over 2 orders of magnitude. In the lower ROI ( Figure 1C ), proportionality between microbubble scattering and the agent concentration is visibly affected by attenuation (note that the slopes for the 3 agents are no longer parallel with the expected 10-dB/decade slope of the dashed line). Moreover, scattering even decreases at the highest concentrations in the lower ROI because of excessive attenuation. Thus, scattering can be determined in the upper ROI, and attenuation can be neglected, since the scattered echo power in this ROI is proportional with the agent concentration, as shown in Figure 1B for concentrations between 10 24 and 10 23 lL/mL. Figure 1D summarizes the results obtained in the upper ROI for both US systems and the different transducers used (note that all data were normalized to those of SonoVue). The scattering of Definity is similar or lower compared to that of SonoVue. Compared to Optison, SonoVue scattering is substantially higher for all conditions used.
In the lower ROI, scattering is affected by attenuation, particularly at the higher concentrations, as shown in Figure 1C by the deviation of the slopes from proportionality. Thus, an apparent scattering-to-attenuation ratio can be determined from data in this lower ROI and can be considered a measure of the performance of the agents. Figure 1E summarizes the results, again normalized to those of SonoVue, and shows that even in the presence of attenuation, the performance of SonoVue is similar to or better than that of Definity but superior compared to Optison for all conditions used.
In Vivo Measurements
In vivo imaging performances of SonoVue and Definity were assessed in the heart and liver of pigs. Despite premedication, a substantial number of Optison microbubbles are still trapped within pulmonary intravascular macrophages, limiting the transpulmonary passage of Optison, as was confirmed by the absence of contrast enhancement in the LV, although contrast enhancement was observed in the right ventricle after injection (data not shown). Thus, imaging performances of Optison were only compared in rabbits.
Cardiac Imaging: Endocardial Border Delineation in Pigs
At the lowest clinical dose, LV border delineation could be assessed with Definity for only less than 1 minute after injection; SonoVue, however, showed longer enhancement, and LV border delineation could be assessed even 2 minutes after injection (Figure 2 ). At the highest clinical dose, the duration of enhancement increased, and LV border delineation could be assessed up to 1 minute for Definity, but for SonoVue, it increased to more than 2 minutes. Figure 2 summarizes the peak enhancement in the LV cavity for both agents at full and half the clinical dose; it shows that the peak enhancement of SonoVue is higher compared to that of Definity. Contrast enhancement was quantified ( Figure 2B ) in the LV cavity for both agents at full and half the clinical dose. Data were normalized to the peak enhancement of SonoVue at 17 lL/kg. Figure 2B shows mean 6 standard deviation values (n 5 2 pigs), calculated from data obtained with the GE Logiq E9 US system.
Liver Imaging in Pigs and Rabbits
SonoVue and Definity showed uniform contrast enhancement in the pig liver at half and full clinical doses, allowing adequate visualization of the complete liver, and contrast enhancement persisted for at least 3 minutes (Figure 3 ). After 4 minutes (late phase), a qualitative visual assessment showed that SonoVue enhancement at half the clinical dose was slightly lower than that of Definity, although at the full clinical dose, no difference was observed. It is worth noting that similar results were observed independently of the US scanner used. Contrast enhancement was quantified with VueBox, and peak enhancement at two depths in the pig liver parenchyma was similar or slightly higher for SonoVue Figure 2 . A, Typical images of contrast enhancement in the LV of a pig after injection of SonoVue and Definity. Images at peak enhancement and at 1, 2, and 3 minutes after microbubble injection are shown. Contrast imaging was performed with the GE Logiq E9 US system (M5S-D transducer). Note: After 3 minutes, no more microbubbles were visible (data not shown). B, The top image shows typical contrast enhancement in the pig LV. An ROI was drawn in the LV (green circle) to measure the peak enhancement for SonoVue and Definity at half and full clinical doses using VueBox. Bar graph data were obtained from 2 pigs, and microbubbles were injected twice for each dose in randomized order. Data were normalized to the peak enhancement (PE) of SonoVue at 17 lL/kg. Data are presented as mean 6 SD. compared to Definity at half the clinical dose; Figure 4 shows mean 6 standard deviation values (n 5 3 pigs) calculated from data obtained with the Toshiba Aplio 500 and GE Logiq E9 US systems; note that data were normalized to the peak enhancement of SonoVue at 17 lL/kg measured in the upper ROI. The peak enhancement at the full clinical dose was slightly higher for SonoVue at both depths in the liver parenchyma. The peak enhancement at the full clinical dose was 2 times higher compared to half the clinical dose, confirming the expected proportionality with the agent concentration also for in vivo imaging. Contrast enhancement of Optison within the rabbit liver parenchyma was lower compared to that of SonoVue at full and half clinical doses ( Figure 5 ). In particular, contrast enhancement of SonoVue lasted longer Figure 4 . Quantitative analysis of peak enhancement for SonoVue and Definity contrast enhancement within a pig liver using VueBox quantification software. Imaging was performed with the Toshiba Aplio 500 (6C1 transducer) and the GE Logiq E9 (C1-6 transducer) US systems. Data were obtained from 3 pigs, and microbubbles were injected twice for each dose in randomized order. Peak enhancement was measured in 2 ROIs, an upper ROI (green) and a lower ROI (yellow), as shown in the typical contrast-enhanced images. For each US scanner, the peak enhancement measured after the injection of microbubbles was normalized to the peak enhancement of SonoVue at 17 lL/kg measured within the upper part of the liver parenchyma. Data are presented as mean 6 SD. Figure 5 . A, Typical images of contrast enhancement in a rabbit liver after injection of SonoVue and Optison. SonoVue was injected at doses of 17 lL/kg (left) and 34 lL/kg (right). Optison was injected at doses of 7.5 lL/kg (left) and 15 lL/kg (right). Contrast imaging was performed with the GE Logiq E9 US system (9L transducer). Images at 1, 2, 3, and 4 minutes after microbubble injection are shown. With Optison, no late-phase enhancement was visible at 2 minutes after injection, even at the higher dose. B, The left image shows typical peak contrast enhancement in a rabbit liver. An ROI was drawn (green circle) to measure the peak enhancement for SonoVue and Optison using VueBox quantification software. Bar graph data were obtained from 3 rabbits, and microbubbles were injected twice for each dose in randomized order. For each US scanner, the peak enhancement measured after the injection of microbubbles was normalized to the peak enhancement of SonoVue at 17 lL/kg. Data are presented as mean 6 SD.
than that of Optison ( Figure 5A ). The normalized peak enhancement at full and half clinical doses was substantially higher for SonoVue compared to that of Optison.
Figure 5B shows mean 6 standard deviation values (n 5 3 rabbits) calculated from data obtained with the GE Logiq E9 and Toshiba Aplio 500 systems.
Discussion
Ultrasound contrast agents dramatically changed the use of US imaging, allowing dynamic detection of tissue flow of both macrovasculature and microvasculature. Since their first commercialization, the use of US contrast agents has been limited to LV opacification/endocardial border delineation for a long time, whereas in Europe, they have been approved for indications including detection and characterization of liver and breast masses and assessment of the vasculature. Thanks to their widely accepted safety profile, [31] [32] [33] the use of US contrast agents is expanding rapidly. In this regard, the use of Lumason, approved in 2014 in the United States, has been recently enlarged to the liver for the detection and characterization of liver masses, whereas in Europe, off-label uses are well recognized and supported by European guidelines. 34 The aim of this work was to compare the imaging performances of the 3 major US contrast agents: namely, Optison, Definity, and SonoVue/Lumason. These agents were compared both in vitro and in vivo using two high-end US scanners with transducers that are clinically used for different applications, such as cardiac, abdominal, and small parts.
For in vitro comparison, imaging performance was assessed according to their scattering and attenuation properties. Indeed, these parameters need to be considered when assessing the performance of the US contrast agents, since at higher concentrations, imaging penetration may be limited, and contrast enhancement may be affected by attenuation at larger depths. Such an undesirable situation is of particular importance during the wash-in phase, immediately after bolus injection, and should be avoided in clinical practice. From both US scanners and the various transducers, results revealed that the echogenicity of SonoVue was similar to or better than that of Definity but superior compared to Optison for all conditions used.
For in vivo comparison, doses of each contrast agent were defined according to published clinical studies and were in agreement with the manufacturer's recommendation. Two doses were selected: namely, the clinical dosage and half the clinical dosage. For these selected doses, the number of microbubbles and the total volume of gas injected for SonoVue/Lumason were 2 times lower compared to Definity, whereas the total injected shell material was substantially higher for Optison (50-fold higher compared to SonoVue/ Lumason).
In the pig heart, both SonoVue and Definity produced efficient LV opacification, allowing endocardial border delineation, particularly when using the highest clinical dose (34 and 3 lL/kg for SonoVue and Definity, respectively). Interestingly, quantitative analysis revealed higher enhancement for SonoVue compared to Definity, which is in agreement with in vitro results. Moreover, the duration of enhancement was longer with SonoVue compared to that of Definity.
In the pig liver, SonoVue and Definity showed similar contrast enhancements and durations of enhancement when used at their clinical doses, but at half the clinical dose, contrast enhancement was longer with Definity. This latter result emphasizes the need for a sufficient contrast agent dose if strong late-phase enhancement is needed. Finally, quantitative analyses did not reveal major differences between both contrast agents, which is in agreement with in vitro results. The comparison of SonoVue to Optison was performed in the rabbit liver and revealed superior imaging performance of SonoVue in terms of both peak enhancement and the duration of enhancement. The longer persistence of SonoVue may be important for the assessment of the portal venous and late phases. It is noteworthy that such a difference was observed at the full clinical and half clinical doses of Optison: ie, 7.5 and 15 lL/ kg. Although only the GE Logiq E9 system with the 9L transducer was used for rabbit liver imaging, in vitro data from various US systems and transducers also revealed better imaging performance of SonoVue compared to Optison.
Several limitations need to be considered. First, two premium high-end US scanners with high contrastspecific detection sensitivity were used in this study. Consequently, data presented in this work demonstrated that the clinical doses of Definity and SonoVue could be reduced by half without compromising contrast detection sensitivity. Nevertheless, whether these results apply to all US scanners should require further investigations.
Second, quantitative analyses showed that Definity contrast enhancement at the recommended dose was lower compared to SonoVue. However, as suggested by published recommendations on the use of US contrast agents, 35 this difference may be compensated for by using a higher dose of Definity, although it may increase attenuation. Furthermore, both in vitro and in vivo comparisons were made using very low fixed MI values (<0.1), which are in accordance with system manufacturers' recommendations. The nonlinear bubble responses detected by contrast-specific imaging modes, such as pulse inversion and amplitude modulation, strongly depends on the MI. Thus, the results presented in this work may change with the use of a different MI. Nevertheless, the MI should always be set properly and not be too high to limit microbubble destruction.
Regarding the in vivo work, pigs require aspirin before treatment to prevent activation of pulmonary intravascular macrophages, which results in substantial microbubble entrapment within the lungs. Nevertheless, despite pretreatment, an absence of contrast enhancement was observed for Optison in the LV of pigs. Limited entrapment of SonoVue and Definity cannot be excluded, which may have affected the comparison results. Such a phenomenon has not been reported in the rabbit.
Due to the limitations of the pig model, SonoVue and Optison could only be compared at shallow depths in the rabbit liver and not at larger depths as in the pig liver. However, considering the homogeneous contrast enhancement of SonoVue in the pig liver and the poor contrast enhancement of Optison in the rabbit liver, ie, a superficial organ, one might also expect superiority of SonoVue versus Optison even at larger depths, as was observed in vitro.
In conclusion, physicochemical characteristics and in vitro and in vivo (pig and rabbit) contrast-enhanced US imaging performances were compared for 3 commercially available US contrast agents: SonoVue (also marketed as Lumason in the United States), Definity, and Optison. Although differences between the agents were observed, physicochemical characteristics measured in this study were in agreement with those provided by the manufacturers.
In vitro data demonstrated that the performance of SonoVue was similar to or better than that of Definity but superior compared to Optison. Similar results were obtained in vivo, although the duration of enhancement in the pig heart was longer for SonoVue compared to Definity, and quantitative analysis revealed higher enhancement for SonoVue. For liver imaging, SonoVue and Definity showed similar contrast enhancements and durations of enhancement, but compared to Optison, both peak enhancement and the duration of enhancement were superior for SonoVue. Thus, in summary, the imaging performance of SonoVue was similar to or slightly better compared to that of Definity, but it was superior compared to Optison, for the conditions used in this study.
